 Angiotensin Receptor Antagonists
"Angiotensin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.
| Descriptor ID |
D057911
|
| MeSH Number(s) |
D27.505.519.162
|
| Concept/Terms |
Angiotensin Receptor Antagonists- Angiotensin Receptor Antagonists
- Antagonists, Angiotensin Receptor
- Receptor Antagonists, Angiotensin
- Angiotensin Receptor Blockers
- Receptor Blockers, Angiotensin
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin Receptor Antagonists".
This graph shows the total number of publications written about "Angiotensin Receptor Antagonists" by people in this website by year, and whether "Angiotensin Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1997 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 1 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2006 | 0 | 2 | 2 | | 2008 | 0 | 1 | 1 | | 2010 | 0 | 3 | 3 | | 2011 | 1 | 1 | 2 | | 2013 | 0 | 3 | 3 | | 2014 | 1 | 0 | 1 | | 2015 | 2 | 2 | 4 | | 2016 | 2 | 1 | 3 | | 2017 | 3 | 0 | 3 | | 2018 | 3 | 2 | 5 | | 2019 | 0 | 2 | 2 | | 2020 | 2 | 1 | 3 | | 2021 | 3 | 9 | 12 | | 2022 | 1 | 8 | 9 | | 2023 | 0 | 5 | 5 | | 2024 | 3 | 3 | 6 | | 2025 | 2 | 2 | 4 | | 2026 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin Receptor Antagonists" by people in Profiles.
-
Jacobs JA, Greene T, Vanneman ME, Kean J, Carter SJ, Shah KS, Pandey A, Derington CG, Zheutlin AR, Fang J, Stehlik J, Fonarow GC, Bress AP. Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2026 06 01; 11(6):506-514.
-
Denburg MR, Goodwin Davies AJ, Maltenfort MG, Mitsnefes MM, Flynn JT, Neu AM, Dixon BP, Glenn DA, Gluck CA, Harshman LA, Katsoufis CP, Leonard MB, Modi ZJ, Pan CG, Patel HP, Patterson LT, Verghese PS, Wilson AC, Jovanovska A, Levondosky R, Levondosky M, Dickinson K, Wieand K, Razzaghi H, Li L, Chen Y, Forrest CB. Comparative Effectiveness of Antihypertensive Medications in Children With Chronic Kidney Disease. JAMA Pediatr. 2026 May 01; 180(5):546-555.
-
Martins EB, Madrini V, Ramos Souza PV, Tavares CAM, Albuquerque MT, Santo KE, Harrington JA, Canonico ME, El Rafei A, Bonaca MP, Guimaraes PO. ANSWER-HF: sacubitril-valsartan reduces NT-proBNP in heart failure due to Chagas cardiomyopathy despite no reverse remodeling. Heart Fail Rev. 2026 Mar 23; 31(1).
-
Chang HY, Liao CT, Heidenreich PA, Allen LA, Sung SH, Chen WJ, Wang TD, Li YH, Hsu CY, Wu YW, Huang N. Implementation of the Get With The Guidelines-Heart Failure Adherence to Science, Implementation in Asia (GWTG-HF A.S.I.A.) Program in Taiwan. J Am Heart Assoc. 2026 Jan 06; 15(1):e047097.
-
Carpenter ML, Cruz E, Hirpara A, Sidrak J, Dayton M, Hogan C. Perioperative Angiotensin-receptor Blocker Use Shows Decreased Rates of Manipulation Under Anesthesia and Revisions After Total Knee Arthroplasty: A Systematic Review. Orthopedics. 2025 Nov-Dec; 48(6):e251-e258.
-
Derington CG, Berchie RO, Scharfstein DO, Andrews RM, Greene TH, Xu Y, King JB, Supiano MA, Sonnen JA, Williamson J, Pajewski NM, Pruzin JJ, Cohen JB, Bress AP. Effect of Initiation and Continuous Adherence to ARBs Versus ACEIs on Risk of Adjudicated Mild Cognitive Impairment or Dementia. J Gerontol A Biol Sci Med Sci. 2025 06 10; 80(7).
-
Sauer AJ, Beon C, Cherkur S, Mallas-Serdynski L, Thomas K, Spertus J, Chahoud G, Mody KP, Saltzberg MT, Goldberg LR, Lindenfeld J, Sweitzer N, Butler J, Kittleson MM, Pina I, Paul S, Lewis EF, Wald J, Allen LA, Jessup M, Congdon M, Kiser R, Yancy C, Fonarow GC. Multiregional Implementation Initiative's Impact on Guideline-Based Performance Measures for Patients Hospitalized With Heart Failure: IMPLEMENT-HF. Circ Heart Fail. 2025 May; 18(5):e012547.
-
Shoji S, Kaltenbach L, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Butler J, Allen LA, Lanfear DE, Thibodeau JT, Chapman BM, Oliver-McNeil SM, Felker GM, Pina IL, Granger CB, Hernandez AF, DeVore AD. Guideline-Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT-HF. J Am Heart Assoc. 2024 Dec 17; 13(24):e036998.
-
Zheng J, Sandhu AT, Bhatt AS, Collins SP, Flint KM, Fonarow GC, Fudim M, Greene SJ, Heidenreich PA, Lala A, Testani JM, Varshney AS, Wi RSK, Ambrosy AP. Inpatient Use of Guideline-Directed Medical Therapy During Heart Failure Hospitalizations Among Community-Based Health Systems. JACC Heart Fail. 2025 Jan; 13(1):43-54.
-
Ku E, Inker LA, Tighiouart H, McCulloch CE, Adingwupu OM, Greene T, Estacio RO, Woodward M, de Zeeuw D, Lewis JB, Hannedouche T, Jafar TH, Imai E, Remuzzi G, Heerspink HJL, Hou FF, Toto RD, Li PK, Sarnak MJ. Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease : A Systematic Review and Retrospective Individual Participant-Level Meta-analysis of Clinical Trials. Ann Intern Med. 2024 07; 177(7):953-963.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|